Notably, DNase I co-administration with Dex significantly decreased CitH3 and PADI4 expression while up-regulating HDAC2 and GRα compared to Dex monotherapy (Fig. 4A and B), indicating that NET degradation restored glucocorticoid sensitivity in CS-induced COPD. This evidence concerns the gene PADI4 and chronic obstructive pulmonary disease.